Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lux

Showing results (201-210 of 233) with videos related to

Pageof 24
Sort By:
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|August 29, 2020
[DNVF Memorandum Health Services Research in Oncology]Christoph Kowalski, Ute-Susann Albert, Walter Baumann, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Breast (Edinburgh, Scotland)|January 8, 2021
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Pageof 24

Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|August 29, 2020
[DNVF Memorandum Health Services Research in Oncology]Christoph Kowalski, Ute-Susann Albert, Walter Baumann, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Breast (Edinburgh, Scotland)|January 8, 2021
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Pageof 24